Corvus Pharmaceuticals (CRVS) Enterprise Value (2016 - 2026)
Corvus Pharmaceuticals' Enterprise Value history spans 12 years, with the latest figure at -$236.7 million for Q1 2026.
- Quarterly Enterprise Value fell 4635.23% to -$236.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$236.7 million through Mar 2026, down 4635.23% year-over-year, with the annual reading at -$56.8 million for FY2025, 9.21% down from the prior year.
- Enterprise Value came in at -$236.7 million for Q1 2026, down from -$56.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$2.9 million in Q3 2025 to a low of -$236.7 million in Q1 2026.
- The 5-year median for Enterprise Value is -$14.7 million (2025), against an average of -$31.9 million.
- Year-over-year, Enterprise Value surged 79.26% in 2022 and then tumbled 4635.23% in 2026.
- Corvus Pharmaceuticals' Enterprise Value stood at -$13.2 million in 2022, then increased by 4.1% to -$12.6 million in 2023, then crashed by 311.76% to -$52.0 million in 2024, then decreased by 9.21% to -$56.8 million in 2025, then tumbled by 317.12% to -$236.7 million in 2026.
- Per Business Quant, the three most recent readings for CRVS's Enterprise Value are -$236.7 million (Q1 2026), -$56.8 million (Q4 2025), and -$2.9 million (Q3 2025).